Asensus Surgical Announces Nagoya University Hospital in Japan to Initiate Senhance Surgery Program
16 Janvier 2024 - 12:55PM
Asensus Surgical, Inc. (NYSE American: ASXC), a medical device
company that is digitizing the interface between the surgeon and
the patient, announced today that Nagoya University Hospital in
Japan has entered into an agreement to lease and utilize a
Senhance® Surgical System in their Pediatric Surgery Department, at
the end of December 2023. This is the first pediatric installation
in Japan and the fourth globally for 2023. This Senhance System was
previously announced in our January 8, 2024, Corporate Update news
release.
"The Senhance System is specifically equipped to meet the
demands of pediatric surgery, and we are excited to work with
Nagoya University Hospital," noted Anthony Fernando, President and
CEO of Asensus Surgical. "With its specialized instrumentation and
advanced clinical intelligence, the system offers a unique
advantage for pediatric patients, reducing invasiveness and
increasing precision in a way that sets it apart. Our experience in
Europe and the United States has shown success in various pediatric
procedures, and we're eager to extend these benefits in Japan."
Nagoya University Hospital, Japan, initiated a
Senhance® Surgical System dedicated to pediatric procedures
"The Senhance System provides a valuable solution for pediatric
surgery," stated Dr. Hiroo Uchida of the Department of Pediatric
Surgery at Nagoya University Hospital. "Designed with smaller
patients in mind, the reusable 3mm instruments offer a distinct
advantage. Having our experience in laparoscopic surgery, we find
the system very adaptable, such as instinctive camera control and
haptic feedback with crucial safety features. In addition, we
believe the system offers economic value. This represents a
significant step forward aligning with our goal of providing the
best care for our young patients."
About Nagoya University Hospital
Established in 1871, Nagoya University Hospital is one of
Japan’s leading medical institutions, with 35 departments and 32
central medical facilities, and accepts about 500,000 outpatients
annually. In 2019, it became the first national university hospital
to obtain certification from the Joint Commission International
(JCI), and it was renewed in March 2022, when it was re-examined.
The hospital's management ethos centers on leveraging leading-edge
technologies to provide the best possible healthcare services.
About Asensus Surgical, Inc.
Asensus Surgical, Inc. is digitizing the interface between the
surgeon and patient to pioneer a new era of Performance-Guided
Surgery™ by unlocking clinical intelligence for surgeons to enable
consistently superior outcomes and a new standard of surgery. Based
upon the foundations of Digital Laparoscopy and the Senhance
Surgical System, the Company is developing the LUNA™ Surgical
System, a next generation robotic and instrument system as a
foundation of its Digital Surgery solution. These systems will be
powered by the Intelligent Surgical Unit™ to increase surgeon
control and reduce surgical variability. With the addition of
machine vision, Augmented Intelligence, and deep learning
capabilities throughout the surgical experience, we intend to
holistically address the current clinical, cognitive and economic
shortcomings that drive surgical outcomes and value-based
healthcare. The Senhance Surgical System is now available for sale
in the US, EU, Japan, Russia, and select other countries. For a
complete list of indications for use, visit:
www.senhance.com/indications. To learn more about
Performance-Guided Surgery, and digital laparoscopy with the
Senhance Surgical System visit www.asensus.com.
Follow Asensus
Email Alerts: https://ir.asensus.com/email-alerts
LinkedIn:
https://www.linkedin.com/company/asensus-surgical-inc/
Twitter: https://twitter.com/AsensusSurgical
YouTube: https://www.youtube.com/@AsensusSurgical
Vimeo: https://vimeo.com/asxc
TikTok:https://www.tiktok.com/@asensus_surgical
Forward-Looking Statements
This press release includes statements relating to the Senhance
Surgical System and Nagoya University Hospital in Japan initiating
a program with the Senhance System. These statements and other
statements regarding our future plans and goals constitute "forward
looking statements" within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934, and are intended to qualify for the safe harbor from
liability established by the Private Securities Litigation Reform
Act of 1995. Such statements are subject to risks and uncertainties
that are often difficult to predict, are beyond our control and
which may cause results to differ materially from expectations and
include whether the Senhance System’s success in pediatric patients
in Europe and the United States will extend to Japan and whether
the Senhance System will help Nagoya University Hospital achieve
its goal of providing the best care for young patients. For a
discussion of the risks and uncertainties associated with the
Company’s business, please review our filings with the Securities
and Exchange Commission (SEC), including our Annual Report on Form
10-K for the year ended December 31, 2022, filed with the SEC on
March 2, 2023 and our other filings we make with the SEC. You are
cautioned not to place undue reliance on these forward looking
statements, which are based on our expectations as of the date of
this press release and speak only as of the origination date of
this press release. We undertake no obligation to publicly update
or revise any forward-looking statement, whether as a result of new
information, future events or otherwise.
INVESTOR CONTACT:
Mark Klausner or Mike Vallie, 443-213-0499
invest@asensus.com
MEDIA CONTACT:
Dan Ventresca
Matter Communications
AsensusPR@matternow.com
617-874-5488
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/41ac9c05-4dfb-4a31-ac83-122e37b9b24f
Asensus Surgical (AMEX:ASXC)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Asensus Surgical (AMEX:ASXC)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024